<SEC-DOCUMENT>0001193125-25-004045.txt : 20250110
<SEC-HEADER>0001193125-25-004045.hdr.sgml : 20250110
<ACCEPTANCE-DATETIME>20250110063018
ACCESSION NUMBER:		0001193125-25-004045
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250109
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250110
DATE AS OF CHANGE:		20250110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Rapport Therapeutics, Inc.
		CENTRAL INDEX KEY:			0002012593
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				880724208
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-42121
		FILM NUMBER:		25520254

	BUSINESS ADDRESS:	
		STREET 1:		1325 BOYLSTON STREET
		STREET 2:		SUITE 401
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02215
		BUSINESS PHONE:		857-321-8020

	MAIL ADDRESS:	
		STREET 1:		1325 BOYLSTON STREET
		STREET 2:		SUITE 401
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02215
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d925938d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:rapp="http://www.rapportrx.com/20250109" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-317">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-01-09_to_2025-01-09">0002012593</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="rapp-20250109.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-01-09_to_2025-01-09"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0002012593</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-09</xbrli:startDate> <xbrli:endDate>2025-01-09</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-328">8-K</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt:datemonthdayyearen" id="ixv-329">January 9, 2025</ix:nonNumeric></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-330">Rapport Therapeutics, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt-sec:stateprovnameen" id="ixv-331">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-332">001-42121</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-333">88-0724208</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or Other Jurisdiction<br/>of Incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(IRS Employer<br/>Identification No.)</span></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-334">1325 Boylston Street</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-335">Suite 401</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-336">Boston</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt-sec:stateprovnameen" id="ixv-337">Massachusetts</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-338">02215</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-339">857</ix:nonNumeric> <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-340">321-8020</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not&#160;Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt-sec:boolballotbox" id="ixv-341">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt-sec:boolballotbox" id="ixv-342">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt-sec:boolballotbox" id="ixv-343">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt-sec:boolballotbox" id="ixv-344">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-345">Common Stock, $0.001 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-346">RAPP</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt-sec:exchnameen" id="ixv-347">The Nasdaq Global Market</ix:nonNumeric></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt-sec:boolballotbox" id="ixv-348">&#9746;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. <ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2025-01-09_to_2025-01-09" format="ixt-sec:boolballotbox" id="ixv-349">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;7.01 Regulation FD Disclosure. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;9, 2025, Rapport Therapeutics, Inc. (the &#8220;Company&#8221;) announced new data from its positron emission tomography (&#8220;PET&#8221;) trial and second multiple ascending dose <span style="white-space:nowrap">(&#8220;MAD-2&#8221;)</span> trial for <span style="white-space:nowrap">RAP-219.</span> A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on <span style="white-space:nowrap">Form&#160;8-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information included under Item 7.01 of this Current Report on Form <span style="white-space:nowrap">8-K,</span> including Exhibit 99.1, is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;8.01 Other Events. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;9, 2025, the Company announced the following results from its recent PET and <span style="white-space:nowrap">MAD-2</span> trials for <span style="white-space:nowrap">RAP-219,</span> based on preliminary analysis of the data: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The PET trial <span style="white-space:nowrap"><span style="white-space:nowrap">(RAP-219-103)</span></span> was an open label trial in healthy volunteers designed to confirm neuroanatomical expression of TARP<span style="FONT-FAMILY:SYMBOL">g</span>8 and establish the relationship between pharmacokinetics (&#8220;PK&#8221;) and brain target receptor occupancy (&#8220;RO&#8221;) with <span style="white-space:nowrap">RAP-219.</span> The trial included three cohorts: Cohort 1 was given the same dosing regimen currently being used in the Phase 2a trial in focal epilepsy (0.75 mg daily for 5 days, followed by 1.25 mg daily for 9 days), and lower doses were used in the other two cohorts to better characterize the plasma concentration versus RO relationship. Cohort 2 was given 0.25 mg daily for 14 days and Cohort 3 was given 0.25 mg daily for 7 days, followed by 0.5 mg daily for 7 days. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PET trial results are summarized below: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The PET data demonstrated that Cohort 1 (the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy) exceeded the target RO range associated with maximal efficacy in prior preclinical models <span style="white-space:nowrap">(50%-70%)</span> within five days of dosing, while maintaining a differentiated tolerability profile generally consistent with prior Phase 1 trial findings. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The trial confirmed that the expression of TARP<span style="FONT-FAMILY:SYMBOL">g</span><span style="white-space:nowrap">8-containing</span> AMPA receptors is enriched in the hippocampus and cerebral cortex and is minimal in the cerebellum and brain stem. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Collectively, data from the PET and <span style="white-space:nowrap">MAD-2</span> trials demonstrated that plasma concentrations and associated target RO could be achieved within 5 days. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <span style="white-space:nowrap">MAD-2</span> <span style="white-space:nowrap"><span style="white-space:nowrap">(RAP-219-104)</span></span> trial was a double-blind, placebo-controlled trial in healthy volunteers and was the second MAD trial of <span style="white-space:nowrap">RAP-219.</span> The trial was designed to further evaluate safety and tolerability with continued dose escalation, as well as to shorten time to reach predicted therapeutic levels of <span style="white-space:nowrap">RAP-219.</span> The trial included three cohorts: Cohort 1 (0.75 mg for 3 days, 1.25 mg for 3 days, 1.75 mg for 2 days), Cohort 2 (0.75 mg for 2 days, 1.25 mg for 2 days, 1.75 mg for 4 days), and Cohort 3 (0.5 mg for 2 days, 1 mg for 2 days, 1.75 mg for 24 days). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">MAD-2</span> trial results are summarized below: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="white-space:nowrap">RAP-219</span> was generally well tolerated. All treatment emergent adverse events were Grade 1 or 2 and generally consistent with tolerability observed in prior Phase 1 trials. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Unlike with many <span style="white-space:nowrap">anti-seizure</span> medications, no sedation or motoric impairments were observed with <span style="white-space:nowrap">RAP-219,</span> consistent with target biology and preclinical observations. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Target exposures and RO were achieved within 5 days of dosing across various dosing regimens. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clinical conduct of the PET and <span style="white-space:nowrap">MAD-2</span> trials is complete, and the clinical study reports for both are in progress. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&#160;9, 2025, the Company also announced that Bradley Galer, M.D., has stepped down as its Chief Medical Officer, and a search for his successor is underway. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;9.01 Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:3%"/>
<td style="width:94%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d925938dex991.htm">Press Release issued by Rapport Therapeutics, Inc. on January&#160;9, 2025, furnished herewith.</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">Rapport Therapeutics, Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: January&#160;10, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Troy Ignelzi</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Troy Ignelzi</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Financial Officer</p></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d925938dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g925938g98k99.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right"><B>Exhibit 99.1</B></TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Rapport Therapeutics Announces New Phase 1 Data, Further Supporting
<FONT STYLE="white-space:nowrap">RAP-219&#146;s</FONT> Transformative Potential for CNS Disorders </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>In the PET trial, <FONT
STYLE="white-space:nowrap">RAP-219</FONT> achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted neuroanatomical expression of TARP</I><FONT
STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><I></I><I>8 was confirmed </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>In the <FONT STYLE="white-space:nowrap">MAD-2</FONT> trial, <FONT
STYLE="white-space:nowrap">RAP-219</FONT> was observed to be generally well tolerated with faster titration and higher exposures than in the initial MAD trial </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Data underscore the potential broad therapeutic index of <FONT STYLE="white-space:nowrap">RAP-219</FONT> and dosing flexibility </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Ongoing Phase 2a trial of <FONT STYLE="white-space:nowrap">RAP-219</FONT> in focal epilepsy is on track and topline data is expected in <FONT
STYLE="white-space:nowrap">mid-2025</FONT> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BOSTON and SAN DIEGO, January</B><B></B><B>&nbsp;9, 2025 &#151; </B>Rapport Therapeutics, Inc. (Nasdaq:
RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients suffering from central nervous system (CNS) disorders, today announced results from its positron emission
tomography (PET) trial and second multiple ascending dose <FONT STYLE="white-space:nowrap">(MAD-2)</FONT> trial for <FONT STYLE="white-space:nowrap">RAP-219.</FONT> Data from the trials demonstrated that
<FONT STYLE="white-space:nowrap">RAP-219</FONT> achieved target receptor occupancy (RO) associated with maximal efficacy in prior preclinical models within five days of dosing while maintaining a differentiated tolerability profile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;These Phase 1 results reinforce our belief in <FONT STYLE="white-space:nowrap">RAP-219&#146;s</FONT> distinct profile and potential to deliver
transformative outcomes for patients,&#148; said Steve Paul, M.D., Rapport cofounder and chair of the board of directors. &#147;The data demonstrate that neuroanatomical specificity can be achieved through
<FONT STYLE="white-space:nowrap">RAP-219&#146;s</FONT> selective targeting of a receptor-associated protein, and <FONT STYLE="white-space:nowrap">RAP-219</FONT> was able to quickly achieve target engagement and therapeutic exposures in the brain
while maintaining a generally favorable tolerability profile. Additionally, the data provide further support for the dosing regimen selected for our ongoing Phase 2a trial in focal epilepsy.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A total of four Phase 1 trials have been conducted to date, with 100 healthy volunteers exposed to <FONT STYLE="white-space:nowrap">RAP-219.</FONT> In these
trials, <FONT STYLE="white-space:nowrap">RAP-219</FONT> was generally well tolerated in multiple repeat-dose studies with up to 28 days of dosing, with no serious adverse events (SAEs), no treatment emergent adverse events (TEAEs) greater than Grade
2, and no clinically relevant laboratory or electrocardiogram (ECG) abnormalities. Three treatment discontinuations occurred (3%) that were attributed to TEAEs. The trials also showed that favorable tolerability was achieved with various dosing and
titration regimens. Rapport believes the pharmacokinetic (PK) and tolerability outcomes from these clinical trials provide compelling translational evidence of selectively targeting TARP<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>8 associated AMPA
receptors to significantly enhance the therapeutic index of AMPA receptor modulation. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Due to the <FONT STYLE="white-space:nowrap">non-specific</FONT> nature of currently available and
other investigational treatments, many patients continue to endure significant side effects, which limit therapeutic efficacy and diminish their quality of life,&#148; said Abe Ceesay, chief executive officer of Rapport. <FONT
STYLE="white-space:nowrap">&#147;RAP-219</FONT> was designed to overcome such limitations, and we believe these compelling new data support our approach as we advance our Phase 2a trial in focal epilepsy, with topline results expected in <FONT
STYLE="white-space:nowrap">mid-2025.&#148;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Also announced today, Bradley Galer, M.D.,&nbsp;has stepped down as chief medical officer of Rapport. A
search for his successor is underway, and the Company is confident that the transition will not disrupt progress across its clinical programs. Dr.&nbsp;Galer will be assisting the transition, and the Company is grateful for his support and
contributions to Rapport over the past two years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+++ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Results from the recent PET and <FONT STYLE="white-space:nowrap">MAD-2</FONT> trials are below, based on preliminary analysis of the data. Clinical conduct of
the PET and <FONT STYLE="white-space:nowrap">MAD-2</FONT> trials is complete, and the clinical study reports for both are in progress. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The PET trial <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">(RAP-219-103)</FONT></FONT> was an open label trial in healthy volunteers designed to confirm neuroanatomical expression of TARP<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>8 and establish
the relationship between PK and brain target RO with <FONT STYLE="white-space:nowrap">RAP-219.</FONT> The trial included three cohorts: Cohort 1 was given the same dosing regimen currently being used in the Phase 2a trial in focal epilepsy (0.75 mg
daily for 5 days, followed by 1.25 mg daily for 9 days), and lower doses were used in the other two cohorts to better characterize the plasma concentration versus RO relationship. Cohort 2 was given 0.25 mg daily for 14 days and Cohort 3 was given
0.25 mg daily for 7 days, followed by 0.5 mg daily for 7 days. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PET trial results are summarized below: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The PET data demonstrated that Cohort 1 (the dosing regimen utilized in the ongoing Phase 2a trial in focal
epilepsy) exceeded the target RO range associated with maximal efficacy in prior preclinical models <FONT STYLE="white-space:nowrap">(50%-70%)</FONT> within five days of dosing, while maintaining a differentiated tolerability profile generally
consistent with prior Phase 1 trial findings. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The trial confirmed that the expression of TARP<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT><FONT
STYLE="white-space:nowrap">8-containing</FONT> AMPA receptors is enriched in the hippocampus and cerebral cortex and is minimal in the cerebellum and brain stem. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Collectively, data from the PET and <FONT STYLE="white-space:nowrap">MAD-2</FONT> trials demonstrated that plasma
concentrations and associated target RO could be achieved within 5 days. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <FONT STYLE="white-space:nowrap">MAD-2</FONT> <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">(RAP-219-104)</FONT></FONT> trial was a double-blind, placebo-controlled trial in healthy volunteers and was the second MAD trial of <FONT STYLE="white-space:nowrap">RAP-219.</FONT> The trial was designed to further
evaluate safety and tolerability with continued dose escalation, as well as to shorten time to reach predicted therapeutic levels of <FONT STYLE="white-space:nowrap">RAP-219.</FONT> The trial included three cohorts: Cohort 1 (0.75 mg for 3 days,
1.25 mg for 3 days, 1.75 mg for 2 days), Cohort 2 (0.75 mg for 2 days, 1.25 mg for 2 days, 1.75 mg for 4 days), and Cohort 3 (0.5 mg for 2 days, 1 mg for 2 days, 1.75 mg for 24 days). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">MAD-2</FONT> trial results are summarized below: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><FONT STYLE="white-space:nowrap">RAP-219</FONT> was generally well tolerated. All TEAEs were Grade 1 or 2 and
generally consistent with tolerability observed in prior Phase 1 trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Unlike with many <FONT STYLE="white-space:nowrap">anti-seizure</FONT> medications, no sedation or motoric
impairments were observed with <FONT STYLE="white-space:nowrap">RAP-219,</FONT> consistent with target biology and preclinical observations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Target exposures and RO were achieved within 5 days of dosing across various dosing regimens.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A Phase 2a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial is currently underway
to evaluate <FONT STYLE="white-space:nowrap">RAP-219</FONT> in patients with refractory focal epilepsy, with topline results expected in <FONT STYLE="white-space:nowrap">mid-2025.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">RAP-219</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">RAP-219</FONT> is a clinical-stage AMPA receptor negative allosteric modulator designed to achieve neuroanatomical specificity through its selective targeting of AMPA-associated protein,
TARP<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>8. AMPA receptors are present throughout the brain, including in the cerebellum and brain stem, where their <FONT STYLE="white-space:nowrap">non-selective</FONT> targeting has resulted in poor
tolerability. In contrast, TARP<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>8 expression is enriched in the hippocampus and cerebral cortex and is minimal in the cerebellum and brain stem. <FONT STYLE="white-space:nowrap">RAP-219</FONT> is designed
to be highly potent and selective for TARP<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>8. It has been observed to have a long half-life (8&#150;14 days) and minimal drug-drug interactions, making it potentially well-suited for polypharmacy. With
this profile, <FONT STYLE="white-space:nowrap">RAP-219</FONT> has the potential to provide improved activity, tolerability, and a higher therapeutic index, potentially providing more patients with sustained therapeutic benefits without intolerable
side effects, as compared to traditional neuroscience medications. As AMPA receptors play critical roles in numerous neurological disorders, selective targeting of TARP<FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT>8&nbsp;may provide a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pipeline-in-a-product</FONT></FONT></FONT> opportunity. The Company is currently pursuing <FONT STYLE="white-space:nowrap">RAP-219</FONT> as a potentially
differentiated treatment for patients with focal epilepsy, diabetic peripheral neuropathic pain, and bipolar mania. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Rapport Therapeutics </B>
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing small molecule precision medicines for patients
suffering from central nervous system (CNS) disorders. The Company&#146;s founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport&#146;s RAP
technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of conventional neurology drug discovery. Rapport&#146;s precision neuroscience pipeline includes the Company&#146;s lead clinical program, <FONT STYLE="white-space:nowrap">RAP-219,</FONT>
designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently advancing <FONT STYLE="white-space:nowrap">RAP-219</FONT> in clinical trials in focal
epilepsy, diabetic peripheral neuropathic pain, and bipolar mania. Additional preclinical and late-stage discovery stage programs are also underway, targeting CNS disorders including chronic pain and hearing disorders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains
&#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act of 1933 and Section&nbsp;21E of the Securities Exchange Act of 1934, each as amended. The words &#147;anticipate,&#148; &#147;believe,&#148;
&#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;target,&#148;
&#147;would&#148; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or
implied statements regarding: the broad therapeutic index of <FONT STYLE="white-space:nowrap">RAP-219</FONT> and its ability to deliver transformative outcomes for patients; the clinical development of <FONT STYLE="white-space:nowrap">RAP-219</FONT>
for the treatment of drug-resistant focal epilepsy, peripheral neuropathic pain and bipolar acute mania, including expected dosing flexibility; the expected timing of the results from ongoing clinical trials; the activity and tolerability of <FONT
STYLE="white-space:nowrap">RAP-219,</FONT> including its neuroanatomical specificity; and Rapport&#146;s RAP technology platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward looking
statements are based on management&#146;s current expectations and are subject to risks and uncertainties that could negatively affect Rapport&#146;s business, operating results, financial condition, and stock value. Factors that could cause actual
results to differ materially from those currently anticipated include: risks relating to the company&#146;s research and development activities, including that interim, topline and preliminary data from our clinical trials that we announce or
publish from time to time are subject to audit and verification procedures that could result in material changes in the final data; Rapport&#146;s ability to execute on its strategy including obtaining the requisite regulatory approvals on the
expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the company&#146;s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its
product candidates, if approved; Rapport&#146;s ability to attract, integrate and retain key personnel; risks related to the company&#146;s financial condition and need for substantial additional funds in order to complete development activities and
commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining
Rapport&#146;s intellectual property protections; and risks related to the competitive landscape for Rapport&#146;s product candidates; as well as other risks described in &#147;Risk Factors,&#148; in the company&#146;s Registration Statement on
Form <FONT STYLE="white-space:nowrap">S-1,</FONT> and most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as well as discussions of potential risks, uncertainties, and other important factors in Rapport&#146;s
subsequent filings with the Securities and Exchange Commission. Rapport expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor
for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact </B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Julie DiCarlo </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Head of Communications&nbsp;&amp; IR </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rapport Therapeutics </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jdicarlo@rapportrx.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>rapp-20250109.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 1/10/2025 10:04:58 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:rapp="http://www.rapportrx.com/20250109"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.rapportrx.com/20250109"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rapp-20250109_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="rapp-20250109_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>rapp-20250109_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 1/10/2025 10:04:58 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>rapp-20250109_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 1/10/2025 10:04:58 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="rapp-20250109.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g925938g98k99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g925938g98k99.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M6%QU2G-*;N@A4:>IZ)7TYV!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M _S8_4T$R;G,]OTGX<>%]*L$MO[)M[M\8>:Y02,Q]>>GX4CK5**5K'F'Q6\
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MUIE461MOFH22"N>I&<8]J#:C--<K.O\ $_B[2O"^F2W-W<QF<*?*MU8;Y&[
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MA!LX<2RAL( ,DG)QQ]:1I%<L;,V(9HIX4FAD62)P&1T.0P/0@]Z"Q] !0 4
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M.IW$HE%S&-J1$=%6/.-OJ,\T#Y7;?4;X?\*W6FZ]=ZWJ-]#<7EQ"(-MO;B%
MH.<D9.YL]Z C!IW9U-!H% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 9WB#_D7-3_Z]I/_ $$T$RV8[0_^1?TW_KVC_P#010$=D7Z"@H *
8 "@ H * "@ H * "@ H * "@ H * /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.4</span><table class="report" border="0" cellspacing="2" id="idm46494256922320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jan. 09, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0002012593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  09,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Rapport Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-42121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">88-0724208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1325 Boylston Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">321-8020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">RAPP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M;:K!.40+OB-/$12>7,FP#-IIOA;)P> RN&9=%@PPPB/;I^<03J((+!$*Y7!
MOL!UY&O:F,H62=IA/7*G]C$T+5<=&GH2QEIW (H:.,ZZV*I&5EQRGDNHW6Z
MIKMN 13W\.\!I^Y,:;)0V^8.BLO=*1=!C*QN"O2LKE"1E6L6T&9:O<LT;,XS
MKOD\P=#JQD!Q:_\>;0:SAL;UI\Q.>DF+8L 8Q2R9UOV"XC9?)' "N]S3*+C
MH'>-@=3-@>*N_D6%$)/91J68M;6(=!B]'$!/QXCJ3D!QQ_ZFI;4BA< D29X>
M;,TT4N%";1L?6ML_Q;U[KF(92BO3-7F&\M:2QXT\N$H;#ZO=G^%6/=.B"(^
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M(SBL3G<!_+]2RGZ<N!< U?N;\;]02P,$%     @ R#,J6I^@&_"Q @  X@P
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M$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ R#,J6@=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M" #(,RI:;P/J].T    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    " #(,RI:F5R<(Q &  "<)P  $P
M    @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ,@S*EHX
MN >X>@0  ,L1   8              " @0P(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    " #(,RI:GZ ;\+$"  #B#   #0
M    @ &\#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( ,@S*EJ7BKL<P
M !,"   +              "  9@/  !?<F5L<R\N<F5L<U!+ 0(4 Q0    (
M ,@S*EH<.&7J/P$  #P"   /              "  8$0  !X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    " #(,RI:)!Z;HJT   #X 0  &@
M@ 'M$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #(
M,RI:99!YDAD!  #/ P  $P              @ '2$@  6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     "0 ) #X"   <%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d925938d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d925938d8k.htm">d925938d8k.htm</File>
    <File>rapp-20250109.xsd</File>
    <File>rapp-20250109_lab.xml</File>
    <File>rapp-20250109_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d925938d8k.htm": {
   "nsprefix": "rapp",
   "nsuri": "http://www.rapportrx.com/20250109",
   "dts": {
    "inline": {
     "local": [
      "d925938d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "rapp-20250109.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "rapp-20250109_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rapp-20250109_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-01-09_to_2025-01-09",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d925938d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-01-09_to_2025-01-09",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d925938d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.rapportrx.com//20250109/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-25-004045-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-004045-xbrl.zip
M4$L#!!0    ( ,@S*EINBK_OCA0  "!^   .    9#DR-3DS.&0X:RYH=&WM
M76MSXCC6_IY?H6*V=])5 6Q#.H&DLY4FZ1YV.I<BF=K9_3(E; %ZVU@>R0XP
MO_X]1[*-S260 $GW5*:J)QCK>G3.<RXZ$J?_&@]]\L"DXB+X^+-=L7XF+'"%
MQX/^QY_/[UKM]L__.ML['410#(H&JNDQ_K$TB**P6:V.N]*O*.96^N*A"B^J
MCN742TG!6)6C2<A45KI'5;<B9+^:OBD4#T00Q,.L\&@TJNCFL8(7R2K6J$*A
M,I1BDKMIO;'/@V^%:J.:KF0W&HVJ?IL6G2N9=>!85JV*K[M4L;2XI&%8*(Y?
M"!G)<<450QS\H65;C6P@BB\:!C1M5W^_^GKG#MB0EGF@(AJX62=Q))<.J5&%
MMVE!KD3=L8\>&7]2(JLP7E;6AK(!S);]_JGS=5H\6EQ^6K0:21JHGI!#&@&_
M8$N'9<LI.Q]RC92!'PH-I?RQJIWC<LW.: F=\\>F.D-%?.O-\&52^$/5O$R*
M+N<4Y/$2\CJC'OR)>.2SL^/RKZ=5\W'O=,@B2K!ZF?T9\X>/I98((A9$Y7O@
MS1)QS=/'4L3&454W5X5:5=,@(>2T*[S)V:G''XB*)C[[6/*X"GTZ0>9GI3-R
MRL=-+,UD\IE['@O,9RAR;3B?!'2(=1EOG@]9X,&_Z+-/^\D(QE&']>!U+#5U
M_T ^+5MVV6K\$8G<4XEP[V.)CQ^ [D>ELQ[U%3NM%GJ:ZQEK_*(']0=T_\=E
M *29M*!_2?UVX+'QKVQ2RHUO28&GC?/,LBQ@$>>P49L?7W6&3)+UF 0(8PJ>
M4:*;2@L>]+5+P- ](41]+"D^#/WLNX'$22)RE%/ J(R5E[ZFTI4".6%U)]5D
MMH49ZF<E8FD>M=PT$_+JU5J#O&DUIA<K>^0>?M'C3!)-0K90JEOM7XL+-%L9
M1[VP_1!64'C9(PBTC"YHQ,ZF8TMK3M]-Q^HM*9N^R;K-^JD6J)-1<TJ]:E[\
MJB"F\"<GK%BK3'W>#YHNS(7)4O']B'O1H'E<.>3!2:ZLSWK1R9#*/@_*^+E)
M:!R)]!O)^X/D*VPN3!M#K"P/F'X+:CG,FHA$V,P]=D44B:'^IBLD##W]Q@['
M1 F?>^0G2_]7.OOG3_8'Z^2T&B[KJ+:Z(^?9'>6:K4,C9'X"I =+4U;\+]:T
MC[/G'AUR?]*\YT.FR#4;D8X8TN!$OQN9<7>%[YTL6)[?KMOWEQ?D[O[\_O)N
M^7"L%QK.W67KMT[[OGUY1\ZO+\CE[ZU?SJ^_7)+6S=55^^ZN?7.]T1B=;8SQ
M/^=WO[2OO]S?7!^0BTJK0ASKL-Z8&==,IZLXL\@0JR1J(6=^>!9G5BPH5F3.
M$R.ECOUN?O9K2NET,BE(+%HPLQPOP%6?;SI7RRV$"^'&:"#D3)1G& C.<<F8
M0D7U^\86.V&+K0@R0$WG\OJ>="YO;SKWKP\LM[%4,0TB$@ERQUSD/$,QNT:$
M)/;AOO?^]4<I>B0:,!Q@+'G$H?[EV!W0H,_(N1L1>&TW:O7EXWRQY44;!X?3
M8>B2DOWTF5&P<9B*"'N DD3JU\Q[WUP-$;?:4+HT]M.3L<*X<X@74=.#!H90
M?>#1R01&Q((\EH#)^6\:Q%1.2.. 8!MON/(2N.+4M\%X2]G(^'H=UN<*_?OH
M&MX\7^/4P(SLF'@+N1\P<*!8''%7'9!VX%96,,S3@,/:!EGV+\<4  +)8<0R
M)0.ABMR%S$5GR",\(.U(D=8 '!HF9P'OC=&7,/HFA-D[C6C79\1EOJ]"ZF)H
MLV25]'-(/2]]3KI*INH*WZ>A8LWTP^,LDN,G-.H,,6S+>I>0KFDEHVQ:J:\'
MXY+Z_U[1@:S5WZ&OGW_QP"3P/O43JIJ)SA9*:COKU4Z'.%<ZW\QI-1FB3-^&
MM,_*7<GH-XQD@I??I \"N&!MZMAZ>0H]DAS#D +'-#6OD)D)P+(##,%2!@7V
MR GH2I0"#!$2L$7#T5T$ZJHEXB"2DY;P-E)]&/W$<$7$0BD>L-N"[JO9H+F9
M3T>@$^<Q#*>$-/?66?V,Q6>+OP(Y/W.?P;LN ,WS =_!.))=KCNV8_^-:'-/
MQ^TD&.9J8FQ,J!KX8L=EZ\BI.];Q8Y3:@?@>OXCT[FN11+?@!JQQ2?X-QKCR
MN'8:3KNRBF9Z083?ORJ#/-?RV(K[O]\2PR%7N('W)"O(WL%8$ >(X>_W1H]_
MA_*ZW^[<D<MAZ(L)DYJ;BO))KD7E_9P8P?_0BOA1C1)MY&YBE1Q:6[$KZL??
MN5WQNE[$"EUR[GF2*97\^0IVO+V!'JF7SNR:<T@^B8FO(F#\NT@R%FWD6]G?
M!56<#:AR6#J[BSEHG[JUP S9 J8MX+KO52+2J6QF 24+TX*/-_)>C((-5N=#
MZ>R30&:=79J#Y?&MPBBT97$C;\$ZYSJ!8'>V_E'I[(HJ1=U!K%@4J>_%J-WJ
MJM[":E#_?SQ\EN<T)=8Q6/^.8R\(!?X=[-F$6!@9NI7 =SRD/KD<,S>.^ ,C
M-STP/IAZ72MVU1Q@C0DN\EJVT1-#XEM1$].8VS]_.G;LHQ-%[IG/PH$(4JM4
M1P_]&,TK<@YLHR?T2&@<,0O+;<C<#?#8#H]6)==,N_TJ8&UN<=R;.HMUJW16
M<^SRL>58ZROV%UNR:Q$9'CX/0Q\8$KAHDU#N=ARJSP#QX'1>ZU"N),EC(L('
MA/<P?!OTF4?N4(60KU1%R3[,6T!W-SNBJYBM=-8:,/>;WKNC(:CC4'*,('3%
MF'29+T:X:O@2%Y,4D&XT &.OC#X8 ^$821HF6]T:Y$B/^P@67!&.V7T>K'HD
MB.+#V(]HP$2L_ E1((^J-]$])!5$%^AE_,ED3U%.MP1B:$<2&DS2=SWPY\0(
MZZ$IP=&95\VEO/3AN=[F5KW)S(6<NI7S_NN,?[N6]BXM=!S?G2Q46LL@]#^2
M1[!>&!R)@\2S5QM;>UTA_"Z%M8J L_(P:R.]&T?U^LD\RJ[A .37F127EFP,
MQ#.Y:*6SA#9 C#QQ2)C;H>_$P"YU< X-J\[LB>-6^+Y]1%J?.\2I614H.(WW
MK Z7O/'O:OZ] RQV@=I!_PJ #-#,WQWS.C\2\TX) TT;RLQS[DJ$M^NT;#LI
MR$^9O)#MD;+XRM:<NE4Q+4Z-XS=IV*(TW$J&2(Y9SSJ9#16Q!*_I&:;QVE)1
M^Y&D8B6+ @7+;HZ$*>NOT@%K2))7=O:[[[<K2Z;--VEZ"6EJ*Q4S^2(R57^3
MJ;5DJL;*]7UWNS*5M+FV3&W=1<L9D,878A*\J7!I7B@B0.H@P727^T/?__;;
M6T[0EH.P:\0OEDQQ@7B\ZI[Y/1XN-)F[[H"X/E7J9;;.GTO"UZ:7I"B>>N/^
M;C*$8OOJA9(-?E"*72<YJ9K!6*) 3!I-0$ >X-LI'A?5PG>W([G":38:9F([
M72U6&\3-#TMG:"/I77'A?CL@_[!@O6T24DD>J!\S$N+!R,'"1+Y7V;Y91I1$
M8(RL;$"1#Z6SSOGM[7<^VY0%4D/I65GHL_8L"LW<_F[]", (3)-KJCSZ)_GB
M"S!YR165WQ;E4+RDH=4./#0^&>E.B*OCXM#B-Q!UIK/I9H+17!&P'L& Q4[[
MI"_%*!J@#1MB@)HJXK$>#TSNN@D+6H=D_IS,]'A,C>SC6A^=F!77 <*T"G0&
MZQ)B[CONK:QI#CO=<A:K6>^$3CJ$-6WCN0YRXZSL=I^L=':YA/0K-N#3:E]T
MK9:IM#O7[3AQW3XL<-UV2Y]V[Q$&/0"V7,CM?&[790"\S'QP,8"7 Z$=CE@Q
M70H(ENSMX,T47&_;F'/C2"#=ES_!SD<<NL;%"6!\\$:R!ZZ@'D@(#5R,15+7
MQ51R+(QW5'A4>LKLZGB/>CNU?9IY.WF.KJSD@_%]-FASA&MW3-!XQ']?YIRM
M<W9]C;/I/_ A>+/[F>R![NTM%A4VG),4_"IG='49K!,87?Z(3A3:E-#TWND@
ML\_ *Q6R^5-#_W>2SB8<YSU/UV=4HDH>:!]O;\4F\W:O-]A[N>1*0(V(#3$/
MQ+)/CBI@N'58/_;-ANSG"W+!E>L+%4M6(<OQZ\,VX.LF(,EQ1\,1R9G' [+\
M>!O91Q3 T3O628+L^LD^>0_H$P# N ABT(E'(TIZ4@P)CP!G!." %(B6)B4<
M<&8H^M#\8((J43=X>WF?-1;I_1. *0)R+^ /[FOS$+0R5< $.E'&$VH-)9VV
M?G5^47;2]E.=:KI!*%W9#MB89<=N5-*JYP!F8;91'NHT*@DP3F%0H*6[#(?8
MBV7 U0!H0M$>&/ NCTBC4;$19[4V;\52XH'8Y+PL4&;E2#!7P"S9<?G7;#R[
MUG9H4O(@NQP)/F/"$LS,! &1K8EFZ-1.F9_9VDD.!^FD>)85E2?>P4("(Z\,
M0#EH'=IE8!Z":O92;NUQGWG)\NL%!XT'7,ET[EM1XQVO:<L=X*+2H5'0><G(
M%TXY[@"ULD [=P2*F:BX^W_0J6$#1GQ.N]PW7>G.:82,CX,ZF)\9SXZ80,=@
M760W[Z IC$9 DNNQ=(\\L8?S$]#CF]7Q!^B6LU"?%65CS>.85<(BI" 8'-"W
M,D=(W>(@5 S.NQG%8SAF+IK8)<0>(T>:PSJ7>/!<O1ZL(G%;J?>2864QRP8H
M##BGIL I&:H\ M"HV6"E\&B4*Z";>A*\99*'5SMY*+2PZCX?@ADI<=C4GRBN
M4@%!D&^^"/(@ 0Q8KYS):HV0S+5L6[7IKH.9]HAJKU.$+" ^[3(_Z15X>L"H
M'X&Z>A ^V-&,2?1 %9@:)O4*M%2/ [X%+)8"" 5SQ>! *C=)PM7]>>>V,,#/
M-]?WY<_G5^VO_VW>_??JT\W7TED_&<VQ7G.FT#,'D$O\!F,LJ $/ 0NB$3C_
M)!Q0@&57? -S$;7U5*7^FE//@!62PD0B6 \6:=8*(T0EUXVA.W>JB3LW637M
M6#Q9.>*2I81+U$0TD(P!E0: '*H)DH ?B*TIWN<@FWIZ"F."H-B-,/2!%0+B
M&D4"R&,P/U;&Z<?RMP/4MPZ=+E-/:*J'@/>A@BE9E:-#,@1K@0)S:5DXA,\3
ML&B,V!D(M2O.3*F&+O7>P"^6D]K@4 0^L<(8A(E>C$0Z.V0'6!JP5-%9E]3%
M=)"_C$<7^E0-*7*+JV^?T[H4+[J,%>G<%):WDA+)R1')FANH7=<CU>-,*M0>
MK7"T8/Y696&A1\%[*\(]%>P4^ZA$]3B$AJ$)SZ1)SH',]C;6/]UT+BX[Y=;-
MUZ_GMW>7S?3#][RQ?OAN>=@RV1-;N/5.]$=P*_4^LI;Q#TN;L!?OWL_UFV]S
MZWOD:Y)_;H\\U1G:#?'PTA<,MD0:A\"VRM!'FVTS> ,.CZ]9+Y7OH"_P_2JL
M>:^M)>8E6CV!611J;4]1I83+]1@TJ [IF ^Q.AZRH("^')4M1],4H!E,)ZT^
MAL)CH,-7*[5#ZUWYR'J7N3;8!PX1SW%H? #M8R9Z@)LK( !#4 81_,.Y 9%X
M3QMPD1EB)'SP_K11.L$P$=K/I,\"^-('B #\4K@S [:)GHP9N*&0G;I57/MI
M"8B\4)[,FSC_7<79,%5B9J6";(*DS[:PUG!&,61IA"3S_*]NSS/K2:$OR@+)
MW<$4,4!YAP -PS V:MD%P0+;"T<O86[Z.Z@&5K5&@*26+@4\%0]SQAK(V/!-
M@-X$:$,!:H&MA_&$!^9/#G+!N2C1D\]V+N=UZR(+UXA!3@-.E:,K8A^M/$+=
M 6</B78$SC_,6: ONT^):/,T8FS5*:W/.J4&^;1K"BH\ANF7P2$,O .DM<NZ
M0H.4Q"7V'O57<1&P&>UIF;@J3".I MBY@9\WHD5WN!=+[18Q3$K 73!%>RR:
MZ"$4; MM/N#X>1!#51W490IDA2;1+_2X?!__X@$GM-O05X0UPV>IDT< __$6
M%F-XI3%KX@,W^6K#>:WT7S,'$[VF6N):I>YD\;MI.2=U+C,/K]",LZ 99T$S
M];R/FOE^^XDS5ZCU6#-.TL[NO;UG0,R;7_BF![>G!]=%@GP\<.KU:" RZ 5@
M4R'G^ A+$V&6M<D$P _4PX .,U>=)@&C+Y)ZZ!II$41Q7>Y+%>!1=!63#\:T
M7.!DO3E7;S*QJ4S\%OC\&TN#$IC@LTI(*&CKLF+\KQBS#(VD#)F7GBPX( %H
M:N8EQXPE&0KPE/!G.H8A1><MDXJ,NY\49CZ8'FB8D1QC57:Y\$7?V!KY6(KI
MS8SQ36[>Y&;3H(3A-C8.=<*&,:_!H]&<O=B;F0;AH( 42I$',&=$K&9BD*_B
M]K12.4''(#;;Q!O[AYBPB%EJ+&+&3-61CK0G%<7>)+D,W&Q48@J0-O6TOA-]
MC.SLWBY=;]/65Z*P<PO.[B=0ZSZ;D"_4QUM<KBH7E0.=T >H%(;:GQD%Z+MP
M?;LR9SURI8'23R[7D88J%/"22MPT!QI@]H2*71>F#D_PH#?R1W3RNGOI#=Q+
M_YPE%.H;JPR6XPR2!(W=;[#O>^^SSI:;_SL_>[4=3%_C\-7>GCE^I?]XU>3O
M.@>F:DL.3#7JV8&II/%='J68Q^F%AYTPL>>).?M/N,GN[)02\Y-77@-_#^K8
M8^-&PZX,HJ$^+PE(W,F2MU1L-D4?2803RP!CFI $E1B"?^6T2I<=7<D1;HYN
MZ<4Y\**Z] V *S(KZ$;GQ6[K6W-!;:N^P_5L"?B6W,+T8$$BAIOLN--U@9%-
M?=WK/AMVF>=--3!">5O_UA_!'_L#9#8_+X&)].GB[#U^G6H>8I=GB.9192^?
M8PNR]I9F^R)IM@M_Y:K]Y?K\_K?.Y>YS&G+)]"9GY\^8RT17KIM;N."0@!=C
MM(#JW!.=8FD,)Y-N0I+8*Z9F1I@>.:!^#U$,&](&1%( <2D.H(YN#I9F('1$
M;4YQ_QV4Z:SZ+')S_1 5X?H*=>GMP6LVL^3\\I8&<?B*6GWQ_#:[@7:';4[5
M9FWE!9./_=K+8W> KJ';4:Z6*'?]JJC=MUOL56R%=+7PEYR:10O*MM+?7-KN
M/<:[X")M@7R:-'<TUB<>RUYQXN>)RJNJJN1>B@EI@[;P_^(O?/#ZQ\:57;2Y
MNZO?\=*"XD+O[#YUO @3@Q_3\$$2_BBRU]3^GC6<3ZOF1ZKU[U>?_3]02P,$
M%     @ R#,J6IIG(H&V%@  [%L  !$   !D.3(U.3,X9&5X.3DQ+FAT;>U<
M6U,<.;)^)X+_H&#"&SBFNP>P&1NPB=,&;+.+#0OLS)GSIJY2=VM<MRE5@7M_
M_7Z9DNK6#338>!\.$V,;JE0E*:]?IC+KS<?+3R?[;SX>#0_W5U?>7!Y?GASM
M'_UO?V=GL/GF%_LKKO_B!H@W[TX/_Q#O/AR<GIR>OUW[_>/QY=&:N+C\X^3H
M[5JD$]6?*CV9%KN?TSR6T=J^6%W!\P<J*52^_^;P^#<_^%J'Q73W]6!;)VM"
M1GJ2X 5J7*S1-+24X;N3(W%P=')R<38\./[\X>W:QAK_?C8\//2__WY\>/GQ
M[=KFQL:S-?'N]/SPZ)RONTGLE3Y6>S(\NSC:]3_LB7&:%/VQC'4TV[W4L3+B
ML[H6YVDL$W?3Z'^KW<V-K%@3PY/C#Y_?K@6\"UJ@6^*Y7^NA7\CVYK.U?1#N
ML+[SFWMZE!9%&M=+]@/;+WCYVE_'7^>-J?R6,CE1_5&NY)>^3HP.U:Z\2G4H
M[K>E_<[BBC2S^\+EXT\?Q,7YP=NUR<[6]LZ+UY.=UU\@#W]F$Z+$Y=NUD],/
MIVLL%O7R.[O<_ULR,MF>_7O1N%B'8:0JTN8D--CXN_VCKU,]TH6P$OBN10O\
M0U*Q+]Z<>7+$,I_HI(_U[VZ]S(H]X2[8=>QNT*7VWF\EU!ROL:)SF65I7HC+
MJ<IEILI"!T8,DR0MD\ ]>S:51HE-<2@+V1/OR[S 6'%1\H,ZF6#I[T\_7U:R
M/]6%ZIM,!FHW2:_QUK7]\^%9?VMSYV\_;;[\=<^\^87&[XO+7"9F3+I4Z"LE
MSM("Z](RPAYR<?#Y0AQJD^:ARHVPQ#J[@3B;6X]!G./]XT1@K^+LZ%(4.1;6
M$W:GJRMW[]5O4@93K:Y4*&02"O4U4"K$+P76J@J1JT!E!7:;!D&9R228]81.
M BB  6&%L31F>M!"PI0OYVJ"M2<"S(JPMQ"/\.TTF:1TWS)L2]I%T]UQ&N '
ME>E(96:VAS<8W L*/)NH,D]E(D$SS8.^9KAK=)J(="PNA^=G;WXYWN_LFW[K
MOQ]^.C[Y8_?BCT_O3D^@%#]M;KS8<]L&\?BQX_W7XEH:$:3)6.<QYN/+_RU.
MWBFHGX:'_2W/N@?SG':<CHS*B>]%*D9*3%0"!8NBF;A6482+$7XE^E_K8BK&
MTF"EHM %+A+I25BF,!NX"(:DI@1/L .9>%[K1+.J8,&.S9ZP4,<?25FR"J),
M2$N#-%>\N*S2Y!%D*Z1KWKA@X:'Z2J*UK-&H% DD<0HPCM17V-%(%[/_UK9/
M%^O: _8UIYY"0WK Y5P&7WC7V >A#Q$2J7$3$J%8=_'H$L();]3?VMC:]A/^
M  TDS_+N].+R]#-OX&+X61P>'WTX[8F_RZ24^8SM.9ET_L=ZTIV>H&4*&)+M
MS3TV^8N\4T\<)\% K'^6)I1_[:ZN@)YGSWM"B@!4(AO6-P5PA!AIB&$P3=(H
MG<Q@@6(8V)F ]<68PBHF&U4-P;U2^<Q*&&QUE&8PKP4QTP#G12*&M@9E!,&&
MP=9L&V-Z#9ABV#AGT%H\86"QQV.5LXSF:2Q(8*#U,++Y55KB]@QZ'HMU.+?G
M-+'U;CTL)90TOW6[(=GG,L+K^"4:/\ $P#9@7A5K-LZK*V!,.@%5IC.Q#@_U
MW$D@;<(HV-M0Q'B'SK!L:;"0D%8%!5K""JZS&7S>LH.\SV5E>^ ?9>O NR!2
M\XL,:!RGB2FL_8-1*Y9'$'->]49'*M;/3Y]CYR8-=&UH8_E5QZ1KXS&D *.@
M0EFNB85XA9,?\#M46"<]0=I)X 3\,200S@)AB:!K+'52X ]=D> G\9X-GQ4O
M,O'.2F5Y.L83 _'8IHK<\,M7>U 8,-HC-R].N=()V!@ *I0YO%*DU;@V(O?&
M;Q!@X+^@\+MCV:MM/_0+9 3Q<@AK&^JE90%]["A/CU[_>D\8"<1_42B"A+*$
M _XT.!STA+<%03I.V=_P=,%4ZIP80_(U2F4>,I<TN EQ, -1T<.:SX;LL>C-
MX1\#VZHA',2U /X6OKL6MFF>EI/I@P&O4; C3  KMB0W6*VLQ+??D%<0M0"_
M>KS-^^H'(1 Y DO A+]*'7P!\'#;\"JCD@FL)!LZ=C(-'UU##H<V1CFD?'5E
MD=37P&:,6"UWDRX2_6$8:@(W-+AG32]Q!/>O$.F)L0LL[@"]EH:@#]TG,5X6
M]0Z<>#VZ!@ZQ_\)B@3$MT&NALWY3"1Z,%+9"1KH,G"L"+53/&BD$_&*J9%3
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MM^O\$,,V@H $67@W=N6M5!CFYD,)9R/J6H@%E1!/ROK_6UFMP-15!%4,\ZT
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M8;OD,MJKRRT>L(\NK\_8?_9!7#SR-U!+ 0(4 Q0    ( ,@S*EINBK_OCA0
M "!^   .              "  0    !D.3(U.3,X9#AK+FAT;5!+ 0(4 Q0
M   ( ,@S*EJ:9R*!MA8  .Q;   1              "  ;H4  !D.3(U.3,X
M9&5X.3DQ+FAT;5!+ 0(4 Q0    ( ,@S*EI6:)P,/@,  % +   1
M      "  9\K  !R87!P+3(P,C4P,3 Y+GAS9%!+ 0(4 Q0    ( ,@S*EJ/
M3H3,JP8  *5)   5              "  0PO  !R87!P+3(P,C4P,3 Y7VQA
M8BYX;6Q02P$"% ,4    " #(,RI:J1"$R]P$   "+@  %0
M@ 'J-0  <F%P<"TR,#(U,#$P.5]P<F4N>&UL4$L%!@     %  4 0 $  /DZ
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>d925938d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rapp-20250109.xsd" xlink:type="simple"/>
    <context id="duration_2025-01-09_to_2025-01-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0002012593</identifier>
        </entity>
        <period>
            <startDate>2025-01-09</startDate>
            <endDate>2025-01-09</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-317">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-01-09_to_2025-01-09"
      id="Hidden_dei_EntityCentralIndexKey">0002012593</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-328">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-329">2025-01-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-330">Rapport Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-331">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-332">001-42121</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-333">88-0724208</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-334">1325 Boylston Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-335">Suite 401</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-336">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-337">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-338">02215</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-339">857</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-340">321-8020</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-341">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-342">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-343">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-344">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-345">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-346">RAPP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-347">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-348">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2025-01-09_to_2025-01-09" id="ixv-349">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
